Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Part of paid clinical trials in Kansas City, Missouri.
- Sponsor
- Haya Therapeutics, Inc.
- Study ID
- NCT07867288
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Nonobstructive Hypertrophic Cardiomyopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Accepted
Interventions
- HTX-001 — DRUGHTX-001 is an investigational antisense oligonucleotide (ASO)
Study Details
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.
Key Dates
- First listed
- Oct 9, 2026
- Start date
- Oct 31, 2026
- Status verified
- Oct 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Open-label evaluation of multiple doses of HTX-001 in participants with symptomatic nHCMOpen label evaluation of multiple doses of HTX-001, across 2-3 dose levels, in participants with symptomatic nHCM who are receiving standard of care therapy
Primary Outcome Measure
Safety and Tolerability [ Time Frame: Through Day 43 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Saint Luke's Health System | Kansas City | Missouri | 64111 | Erika Hutt Centeno, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Kansas City, MO
By research site